Cleared Traditional

K023433 - VARELISA CARDIOLIPIN ANTIBODIES SCREEN, MODELS 15848 AND 15896

K023433 is an FDA 510(k) clearance for VARELISA CARDIOLIPIN ANTIBODIES SCREEN, manufactured by Pharmacia Diagnostics GmbH & Co. KG. The device is a Class 2 Immunology device with product code MID cleared through the Traditional 510(k) pathway after a 29-day FDA review.

K023433 · Pharmacia Diagnostics GmbH & Co. KG · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2002
Decision
29d
Days
Class 2
Risk

K023433 is an FDA 510(k) clearance for the VARELISA CARDIOLIPIN ANTIBODIES SCREEN, MODELS 15848 AND 15896. Classified as System, Test, Anticardiolipin Immunological (product code MID), Class II - Special Controls.

Submitted by Pharmacia Diagnostics GmbH & Co. KG (Freiburg, DE). The FDA issued a Cleared decision on November 13, 2002 after a review of 29 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Pharmacia Diagnostics GmbH & Co. KG devices

FDA 510(k) Submission Details - K023433

510(k) Number K023433 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 15, 2002
Decision Date November 13, 2002
Days to Decision 29 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
76d faster than avg
Panel avg: 105d · This submission: 29d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MID Device Classification - Class 2, Special Controls

Product Code MID System, Test, Anticardiolipin Immunological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MID System, Test, Anticardiolipin Immunological

All 77
Devices cleared under the same product code (MID) and FDA review panel - the closest regulatory comparables to K023433.
BINDAZYME HUMAN ANTI-PHOSPHATIDYLSERINE IGA, IGG AND IGM ENZYME IMMUNOASSAY KIT
K032240 · The Binding Site, Ltd. · Sep 2003
MODIFICATION TO REAADS ANTI-PHOSPHATIDYLSERINE IGA SEMI-QUANTATIVE TEST KIT
K024195 · Corgenix, Inc. · Jan 2003
REEADS ANTI-PHOSPHATIDYLSERINE IGG/IGM SEMI-QUANTITATIVE TEST KIT
K024196 · Corgenix, Inc. · Jan 2003
REAADS IGA ANTI-CARDIOLIPIN SEMI-QUANTITATIVE TEST KIT, MODEL 026-001
K022990 · Corgenix, Inc. · Sep 2002
REAADS ANTI-CARDIOLIPIN IGG/IGM SEMI-QUANTITATIVE TEST KIT, MODEL 023-001
K022992 · Corgenix, Inc. · Sep 2002
DIASTAT TOTAL ANTI-CARDIOLIPIN, MODEL FCAR 100T
K020156 · Axis-Shield Diagnostics, Ltd. · Mar 2002